Fig. 3

Case illustration. A 60-year-old female diagnosed with de novo glioblastoma (IDH1wt, MGMT promoter un-methylated) was diagnosed with progression of disease following concomitant RT/temozolomide and 4 adjuvant cycles of temozolomide. She was enrolled in Cohort-3 of the Glitpni trial. Initial progression on MRI of the brain (illustrated by representative coronal gadolinium enhanced T1 images) evolved to a complete response that persisted up to week 103